Drug intelligence / Profile preview

fluconazole + secnidazole

Development stage: Unknown
Lead developer: Alparis
Modality: Small Molecules
Administration: Oral

Overview

Fluconazole + secnidazole is a combination medication used primarily for the treatment of vaginal infections. This combination targets both fungal and protozoal infections simultaneously. Fluconazole is an antifungal medication that works by inhibiting fungal growth through damaging and causing leakage to the fungal cell membrane. Secnidazole is an antiprotozoal medication that works by interfering with the DNA synthesis of parasites, leading to their death. This combination is particularly effective for mixed vaginal infections and is often prescribed as part of syndromic management of vaginal discharge.

Targets

DNACYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on fluconazole + secnidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluconazole + secnidazole.

Explore the full profile